Walking for Hypothyroidism Trial (WHT)
Key facts
- Where
- Karachi, PakistanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 35 and 55 years old?
Source: NCT07205042, who can take part
Where in Pakistan
- University of KarachiKarachi, PakistanContact: Shamoon NoushadNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Karachi
- Trial code
- NCT07205042
- Record updated
- 3 October 2025
- Original description
Women with hypothyroidism often report persistent fatigue, weight gain, autonomic dysregulation, and stress despite stable levothyroxine therapy. This single-center, parallel-group RCT will test whether a structured, supervised 12-week walking program improves basal metabolic rate (BMR) and psychophysiological outcomes compared with usual activity. One hundred twenty women aged 35-55 with stable primary hypothyroidism will be randomized 1:1 to intervention or control.Read full original descriptionShow less
A Randomized Controlled Trial of a 12-Week Walking Program on Metabolic and Psychophysiological Outcomes in Women With Hypothyroidism
Women with hypothyroidism often report persistent fatigue, weight gain, autonomic dysregulation, and stress despite stable levothyroxine therapy. This single-center, parallel-group RCT will test whether a structured, supervised 12-week walking program improves basal metabolic rate (BMR) and psychophysiological outcomes compared with usual activity. One hundred twenty women aged 35-55 with stable primary hypothyroidism will be randomized 1:1 to intervention or control.
Inclusion: Female, aged 35-55 years; Primary hypothyroidism with documented prior TSH >4.5 mIU/L; Stable levothyroxine dose for at least 6 months; Sedentary lifestyle (<150 minutes of moderate-vigorous activity per week); BMI between 20-35 kg/m²; Able to walk unaided; Willing and able to provide written informed consent.
Exclusion: Use of beta-blockers, systemic corticosteroids, or medications significantly affecting heart rate, HRV, or metabolism; Uncontrolled hypertension, insulin-dependent diabetes, symptomatic cardiovascular disease, or orthopedic conditions limiting walking; Major psychiatric hospitalization in the past 12 months; Pregnant or lactating, or planning pregnancy during the study period; Participation in another interventional trial within the past 30 days.